

**REMARKS**

Claims 16, 18-31 and 38-44 are pending in the application before entry of this amendment. Claims 38-44 have been withdrawn from consideration due to a restriction requirement. By way of this amendment, claims 38-44 have been canceled, and no claims have been amended or newly added. No new matter has been added.

The Ex Parte Quayle action mailed July 14, 2011 indicates that the instant application is in condition for allowance except for claims 38-44, which the Office has officially determined to be restricted outside the scope of independent claim 16. In order to move the application to allowance, Applicants have cancelled claims 38-44. Allowance of remaining claims 16 and 18-31 is respectfully requested.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Applicants respectfully submit that the instant application is in condition for allowance, which action is respectfully requested. The Examiner is invited to contact the undersigned at (919) 483-8160, to discuss this case, if desired.

Respectfully submitted,



J. Scott Young  
Attorney for Applicants  
Reg. No. 45,582

Date: Sep 6 2011  
GlaxoSmithKline Inc.  
Five Moore Drive, PO Box 13398  
Research Triangle Park, NC 27709  
(919) 483-8160  
fax: (919) 483-7977  
Scott.S.Young@GSK.com